BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12125628)

  • 1. Anti-HIV agents. Efavirenz versus indinavir: who really wins?
    TreatmentUpdate; 2000 Feb; 12(1):4-5. PubMed ID: 12125628
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral rounds. When success is a pain.
    Bartlett JG; del Rio C
    AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
    [No Abstract]   [Full Text] [Related]  

  • 3. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trials group: two studies are now open to patients who qualify.
    Craig K
    HIV Clin; 2000; 12(1):5. PubMed ID: 11810862
    [No Abstract]   [Full Text] [Related]  

  • 6. DMP 266 and indinavir combination.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
    [No Abstract]   [Full Text] [Related]  

  • 7. Efavirenz in HIV infection.
    Casado JL; Moreno S
    N Engl J Med; 2000 Apr; 342(17):1290-1. PubMed ID: 10787332
    [No Abstract]   [Full Text] [Related]  

  • 8. Treating advanced HIV infection.
    Boffito M; Bonora S; Sinicco A; Raiteri R; Milia MG; Khoo SH; Hoggard PG; Back DJ; Di Perri G
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):344-5. PubMed ID: 14600582
    [No Abstract]   [Full Text] [Related]  

  • 9. Four-drug regimens may be better.
    AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11119435
    [No Abstract]   [Full Text] [Related]  

  • 10. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 11. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
    Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P
    HIV Med; 2005 Nov; 6(6):410-20. PubMed ID: 16268823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New study shows efavirenz effective with d4T and 3TC.
    AIDS Alert; 1999 May; 14(5):60. PubMed ID: 11366404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort.
    Hirschel B; Flepp M; Bucher HC; Zellweger C; Telenti A; Wagels T; Bernasconi E; Ledergerber B;
    AIDS; 2002 Feb; 16(3):381-5. PubMed ID: 11834949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choosing the best initial therapy for HIV-1 infection.
    Clumeck N
    N Engl J Med; 1999 Dec; 341(25):1925-6. PubMed ID: 10601514
    [No Abstract]   [Full Text] [Related]  

  • 15. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
    N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial.
    Haas DW; Fessel WJ; Delapenha RA; Kessler H; Seekins D; Kaplan M; Ruiz NM; Ploughman LM; Labriola DF; Manion DJ
    J Infect Dis; 2001 Feb; 183(3):392-400. PubMed ID: 11133370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
    N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleoside-free regimen tested.
    AIDS Patient Care STDS; 2003 Jun; 17(6):309-10. PubMed ID: 12889482
    [No Abstract]   [Full Text] [Related]  

  • 20. DMP 266 on the horizon.
    Vazquez E
    Posit Aware; 1997; 8(5):25. PubMed ID: 11364636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.